BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
Policy, regulations, AI and CRDMO take centre stage at the flagship event of the Department of Pharmaceuticals
Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
The centre offers a full spectrum of FDA-approved services, including physiotherapy, occupational therapy, speech and language therapy, and aqua therapy
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
The three-day conference is expected to bring together more than 3,000 physiotherapists, clinicians, researchers, academicians, and students
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
